ArticleJournal for immunotherapy of cancer2022

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.

Xin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.